ICONOVO AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.1 SEK | +1.50% |
|
+1.25% | -29.87% |
| 25/04 | Iconovo AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 11/03 | Iconovo AB and Affilogic to Present Positive Data from a Feasibility Study on Nanofitins in ICOone | CI |
| Sales 2023 | 7.08M 642K 53.6M | Sales 2024 * | 45.65M 4.14M 346M | Capitalization | 95.22M 8.64M 721M |
|---|---|---|---|---|---|
| Net income 2023 | -45M -4.08M -341M | Net income 2024 * | -26M -2.36M -197M | EV / Sales 2023 | 16.6 x |
| Net cash position 2023 | 18.48M 1.68M 140M | Net cash position 2024 * | 38.6M 3.5M 292M | EV / Sales 2024 * | 1.24 x |
| P/E ratio 2023 |
-2.63
x | P/E ratio 2024 * |
-4.05
x | Employees | 31 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 36.29% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +1.50% | ||
| 1 week | +1.25% | ||
| Current month | -6.03% | ||
| 1 month | -6.03% | ||
| 3 months | -22.12% | ||
| 6 months | -22.12% | ||
| Current year | -29.87% |
1 week
7.56
8.46
1 month
7.509.00
Current year
7.4612.55
1 year
7.4640.00
3 years
7.4699.80
5 years
7.4699.80
10 years
7.4699.80
| Managers | Title | Age | Since |
|---|---|---|---|
Johan Wäborg
CEO | Chief Executive Officer | 47 | 14/20/14 |
Orest Lastow
FOU | Founder | 60 | 01/13/01 |
Henrik Simonsen
DFI | Director of Finance/CFO | 61 | 01/23/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | 63 | 01/13/01 | |
Gunnar Gårdemyr
CHM | Chairman | 65 | 01/21/01 |
Ann Gidner
BRD | Director/Board Member | 58 | 01/21/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/24/30 | 8.1 | +1.50% | 40,641 |
| 29/24/29 | 7.98 | +2.84% | 102,465 |
| 26/24/26 | 7.76 | -3.00% | 72,437 |
| 25/24/25 | 8 | -1.23% | 85,100 |
| 24/24/24 | 8.1 | +2.79% | 40,587 |
Delayed Quote Nasdaq Stockholm, April 30, 2024 at 04:24 pm IST
More quotes
Iconovo AB is a Sweden-based company, which offers inhalation solutions for pharmaceutical companies. Solutions are based on the Companyâs device platforms and include formulation, analytical testing and documentation. Iconovo Ab develops products, which are a part of device family and include: ICOres, reservoir devices, ICOone, disposable unit-dose devices, ICOcap, capsule-based devices and ICOpre, pre-metered devices. Moreover, the Company offers programs, which include development of generic inhalation products, where the products are registered based on therapeutic equivalence; development of inhalation products based on a generic application programming interface (API) and new chemical entity (NCE); as well as phase I-II clinical trials using ICOone.
Calendar
12/07/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -29.87% | 8.67M | |
| +9.43% | 27.27B | |
| -29.83% | 3.12B | |
| -15.97% | 2.53B | |
| +18.11% | 2.47B | |
| +3.70% | 2B | |
| -9.47% | 1.91B | |
| -2.22% | 1.48B | |
| +2.78% | 1.3B | |
| +18.92% | 1.18B |
- Stock Market
- Equities
- ICO Stock
